secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001564590-22-028755
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences Q2 net loss $24.5M; discontinues vebicorvir, restructures
------------------------------------------------------------------------------

- Cash and securities of $128.6M as of June 30, 2022, projected to fund operations into first half of 2024.
- Net loss $24.5M ($0.51/share) vs $23.6M ($0.55) in Q2 2021; R&D expense $17.8M, G&A $6.8M.
- Discontinued first-gen core inhibitor vebicorvir (VBR) and restructured to prioritize next-gen candidates 3733 and 4334.
- Initiated Phase 1b trial of next-gen core inhibitor ABI-H3733; initial data expected 2H 2022.
- Introduced new small molecule IFNAR agonist research program for HBV/HDV with oral dosing potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000156459022028755/0001564590-22-028755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000156459022028755/asmb-8k_20220809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer